Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Italy
  4. Borsa Italiana
  5. MolMed S.p.A.
  6. News
  7. Most relevant
    MLM   IT0001080248

MOLMED S.P.A.

(MLM)
SummaryChartsNewsCompanyFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about MOLMED S.P.A.
2022AGC Biologics and W.L. Gore & Associates Collaborate on New Protein A-Based Purificatio..
CI
2022RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell..
CI
2021AGC Biologics Partners with BioNTech SE to Further Supply Plasmid DNA Starting Material..
CI
2020MolMed Announces Transition of Luca Alberici from the Role of Chief Business Officer
CI
2020Molmed S P A : CS_ integrativo del Comunicato dimissioni consiglieri
PU
2020MolMed S.p.A.(BIT:MLM) dropped from S&P Global BMI Index
CI
2020AGC Inc. completed the acquisition of 93.2% in MolMed S.p.A. from Finanziaria d'investi..
CI
2020Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collab..
CI
2020Italy to use vetting powers in Molmed acquisition by Japan's AGC
RE
2020University Of Tartu : Novel DNA analysis will help to identify food origin and counterfeit..
AQ
2020Karolinska Institutet : Overlooked protein could play important part in pneumonia and COVI..
AQ
2020University Of Bristol : UK genome analysis has important implications for COVID-19 clinica..
AQ
2020AGC Inc. entered into an agreement to acquire MolMed S.p.A. from Finanziaria d'investim..
CI
2020Molmed S.P.A. Reports Earnings Results for the Full Year Ended December 31, 2019
CI
2020Molmed S P A : RhoVac announces appointment of Professor Anne J. Ridley to its Scientific ..
AQ
2019Molmed S P A : UCT Shines At L'oréal-Unesco Sub-Saharan Africa
AQ
2019Molmed S.P.A. Reports Earnings Results for the Third Quarter Ended September 30, 2019
CI
2019Molecular Medicine : MolMed to present its CDMO services at 2019 CAR-TCR Summit in Boston
PU
2019Molmed S.P.A. Reports Earnings Results for the Half Year Ended June 30, 2019
CI
2019Molecular Medicine : MolMed announces the decision to suspend the enrollment of new patien..
PU
2019Molecular Medicine : MolMed at the 22nd ASGCT congress on continuous innovation in the pro..
PU
2019Molecular Medicine : Shareholders meeting approved the Financial Statement 2018. Incerti c..
PU
2019Molecular Medicine : MolMed at the “Cell & Gene Meeting on the Med” conference..
PU
2019Molecular Medicine : Notice of publication of the Annual Report 2018 and other documents (..
PU
2019Molmed : Riccardo Palmisano reappointed representative of small and medium enterprises wit..
PU
2019Molecular Medicine : MolMed received the authorization to start clinical investigation wit..
PU
2019Molecular Medicine : Board of Directors approved 2018 Full Year financial results
PU
2019Molecular Medicine : Partnership with Rocket Pharma in the field of rare genetic diseases ..
PU
2019Molecular Medicine : MolMed and Genenta Science confirm and extend their partnership in th..
PU
2019Molmed : the protocol of the in-man trial on CAR T CD44v6 presented at EHA (European Hemat..
PU
2019Molecular Medicine : Opinion of the Commission HAS on Zalmoxis« reimbursability in France
PU
2018Molecular Medicine : PR_Publication of the minutes of Shareholders Meeting of Oct 25 and o..
PU
2018Molecular Medicine : Interim financial results as of September 30th 2018
PU
2018Molecular Medicine : MolMed and Dompé mutually terminate the license and distribution agre..
PU
2018Molmed S.P.A. Reports Earnings Results for Third Quarter and Nine Months Ended Septembe..
CI
2018Molecular Medicine : October 25th 2018 Ordinary and Extraordinary Shareholders Meeting Out..
PU
2018Molecular Medicine : A new study confirms the high potential of on CAR T CD44v6 also in so..
PU
2018Molmed : announcement with reference to the shareholders meeting of October 25th 2018.
PU
2018Molecular Medicine : Carlo Incerti succeeds to Claudio Bordignon as Chairman of the Board...
PU
2018Molecular Medicine : MolMed appoints Mr. Salvatore Calabrese Chief Financial Officer
PU
2018Molecular Medicine : Publication of the Interim Financial Report at June 30th 2018
PU
2018Molecular Medicine : MolMed signs a new, three-year agreement for the development and supp..
PU
2018Molecular Medicine : Resignation of the Officer Responsible for the preparation of financi..
PU
2018MolMed S.p.A. and AbCheck s.r.o. Sign A Three-Year Master Agreement for the Development..
CI
2018Molecular Medicine : New and relevant data on the therapeutic potential of NGR-hTNF in bra..
PU
2018Molecular Medicine : MolMed and Glycostem announce the execution of a binding termsheet fo..
PU
2018Molecular Medicine : Further data on the safety of CAR-T CD44v6 result from a study by S. ..
PU
2018Molecular Medicine : 5th tranche of the share capital increase reserved to Société Général..
PU
2018Molecular Medicine : Utilization request concerning the 5th tranche of the share capital i..
PU
2018Molecular Medicine : Full results of NGR-hTNF trial in mesothelioma published by The Lance..
PU
2018MolMed S.p.A. Announces Earnings Results for the First Quarter Ended March 31, 2018
CI
2018Molecular Medicine : Publication of the minutes of Shareholders Meeting of April 12nd 2018
PU
2018Molecular Medicine : MolMed signs Master Service Agreement with Boston Children's Hospital..
PU
2018Molmed : the Shareholders' Meeting approves 2017 Financial Statements
PU
2018Molecular Medicine : MolMed and Orchard Therapeutics announce the beginning of their colla..
PU
2018MolMed S.p.A. Reports Earnings Results for the Full Year Ended of December 31, 2017
CI
2018Molmed And Miltenyi Biotec : EMA approves the utilization of the CliniMACS Prodigy« equipm..
PU
2018Molmed : AIFA Determina on reimbursement regime and market price for the proprietary cell ..
PU
2018Molmed : Dompé exercises the option right to undertake the market access and commercializa..
PU
2018Zalmoxis« : price & reimbursement in Germany, where the product can be prescribed and reim..
PU
2017Molecular Medicine : AIFA set the reimbursement price for Zalmoxis« at EUR 149.000 per inf..
PU
2017Molecular Medicine : Board of Directors examined the business performance and approved the..
PU
2017Molmed S.P.A. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
2017Molecular Medicine : New relevant safety data of CD44v6 CAR-T cells will be presented at t..
PU
2017MolMed S.p.A. announced that it has received funding from Société Générale Capital Part..
CI
2017Molecular Medicine : MolMed will attend the 2nd EBMT INTERNATIONAL TRANSPLANT COURSE in Ba..
PU
2017Molmed : submitted the utilization request concerning the second tranche of the share capi..
PU
2017Molecular Medicine : MolMed and Cellectis signed a development and manufacturing agreement..
PU
2017MolMed S.p.A. Announces Earnings Results for the Six Months Ended June 30, 2017
CI
2017Molecular Medicine : MolMed and Dompé signed strategic commercialization and supply agreem..
PU
2017Molmed S.p.a. : mandate of Liquidity Provider assigned to Mediobanca
PU
2017MolMed S.p.A. and TTY Biopharm Company Ltd Announce Exclusive License and Distribution ..
CI
2017Molecular Medicine : MolMed provides update on Zafiride Conditional Marketing Authorizatio..
PU
2017MolMed S.p.A. Reports Earnings Results for the First Quarter Ended March 31, 2017
CI
2017Megapharm Enters into Distribution and Licensing Agreement with MolMed for Zalmoxis
CI
1  2  3Next